CL2008000578A1 - Anticuerpo antagonista aislado anti-receptor ox40 humano; molecula de acido nucleico que lo codifica; vector y celula huesped; metodo de produccion; composicion que lo comprende; su uso para tratar trastornos mediados por ox40; y metodo para detectar - Google Patents
Anticuerpo antagonista aislado anti-receptor ox40 humano; molecula de acido nucleico que lo codifica; vector y celula huesped; metodo de produccion; composicion que lo comprende; su uso para tratar trastornos mediados por ox40; y metodo para detectarInfo
- Publication number
- CL2008000578A1 CL2008000578A1 CL200800578A CL2008000578A CL2008000578A1 CL 2008000578 A1 CL2008000578 A1 CL 2008000578A1 CL 200800578 A CL200800578 A CL 200800578A CL 2008000578 A CL2008000578 A CL 2008000578A CL 2008000578 A1 CL2008000578 A1 CL 2008000578A1
- Authority
- CL
- Chile
- Prior art keywords
- codifies
- understands
- disorders
- treat
- vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90369307P | 2007-02-27 | 2007-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008000578A1 true CL2008000578A1 (es) | 2008-10-10 |
Family
ID=39620235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200800578A CL2008000578A1 (es) | 2007-02-27 | 2008-02-26 | Anticuerpo antagonista aislado anti-receptor ox40 humano; molecula de acido nucleico que lo codifica; vector y celula huesped; metodo de produccion; composicion que lo comprende; su uso para tratar trastornos mediados por ox40; y metodo para detectar |
Country Status (20)
Country | Link |
---|---|
US (1) | US20100136030A1 (es) |
EP (1) | EP2125891A2 (es) |
JP (1) | JP2010518873A (es) |
KR (1) | KR20100014588A (es) |
CN (1) | CN101668776A (es) |
AR (1) | AR065506A1 (es) |
AU (1) | AU2008219666A1 (es) |
BR (1) | BRPI0807269A2 (es) |
CA (1) | CA2679399A1 (es) |
CL (1) | CL2008000578A1 (es) |
CO (1) | CO6231009A2 (es) |
CR (1) | CR11042A (es) |
EC (1) | ECSP099656A (es) |
IL (1) | IL200572A0 (es) |
MA (1) | MA31246B1 (es) |
MX (1) | MX2009009194A (es) |
PE (1) | PE20090689A1 (es) |
RU (1) | RU2009135824A (es) |
TW (1) | TW200846367A (es) |
WO (1) | WO2008106116A2 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9163085B2 (en) | 2010-08-23 | 2015-10-20 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of treating cancer |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
BRPI0621065A2 (pt) | 2005-12-16 | 2011-11-29 | Genentech Inc | anticorpo anti-ox40l, anticorpos isolados, polinucleotìdeo, vetor, célula hospedeira, método para fabricar um anticorpo anti-ox40l, método para tratar ou previnir uma disfunção imune, composição e uso de um anticorpo anti-ox40l |
CA2749539C (en) | 2009-01-21 | 2022-07-19 | Amgen Inc. | Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases |
MA33122B1 (fr) * | 2009-02-17 | 2012-03-01 | Ucb Pharma Sa | Molecules d'anticorps ayant une specificite pour ox40 humain |
WO2013008171A1 (en) * | 2011-07-11 | 2013-01-17 | Glenmark Pharmaceuticals S.A. | Antibodies that bind to ox40 and their uses |
AU2012299421B2 (en) * | 2011-08-23 | 2016-02-04 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
EP2900061B1 (en) * | 2012-09-17 | 2020-01-22 | Galectin Therapeutics Inc. | Method for enhancing specific immunotherapies in cancer treatment |
SG11201507781VA (en) | 2013-03-18 | 2015-10-29 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
CA2943326A1 (en) | 2014-04-11 | 2015-10-15 | Novartis Ag | Methods of selectively treating asthma using il-13 antagonists |
NZ726513A (en) | 2014-05-28 | 2023-07-28 | Memorial Sloan Kettering Cancer Center | Anti-gitr antibodies and methods of use thereof |
US11111284B2 (en) | 2014-08-21 | 2021-09-07 | The General Hospital Corporation | Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing |
TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗-ox40抗體及其用途 |
US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
CN114504652A (zh) * | 2015-03-03 | 2022-05-17 | 科马布有限公司 | 抗体、用途和方法 |
EP3268387A4 (en) * | 2015-03-11 | 2018-10-10 | Providence Health & Services - Oregon | Compositions and methods for enhancing the efficacy of cancer therapy |
JP6878301B2 (ja) | 2015-04-09 | 2021-05-26 | コーネル ユニヴァーシティー | アレルゲンに対する反応を予防するための遺伝子治療 |
UA126270C2 (uk) | 2015-04-10 | 2022-09-14 | Емджен Інк. | Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин |
KR20180015650A (ko) | 2015-05-07 | 2018-02-13 | 아게누스 인코포레이티드 | 항-ox40 항체 및 이의 사용 방법 |
MY188049A (en) | 2015-05-29 | 2021-11-12 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof |
US20190022092A1 (en) | 2015-09-15 | 2019-01-24 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist |
JP6904947B2 (ja) * | 2015-09-22 | 2021-07-21 | スプリング バイオサイエンス コーポレーション | 抗ox40抗体及びその診断用途 |
US10624974B2 (en) * | 2015-10-15 | 2020-04-21 | Dingfu Biotarget Co., Ltd. | Anti-OX40 antibody and application thereof |
CA3007233A1 (en) * | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
WO2017134292A1 (en) * | 2016-02-04 | 2017-08-10 | Glenmark Pharmaceuticals S.A. | Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis |
JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗pd-l1およびil-2サイトカイン |
TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
JP7291339B2 (ja) * | 2016-12-26 | 2023-06-15 | 協和キリン株式会社 | ミエリンオリゴデンドロサイト糖タンパク質に結合する抗体 |
US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
CN110461356A (zh) | 2016-12-29 | 2019-11-15 | 迈阿密大学 | 用于调节肺中炎性体活性和炎症的方法 |
KR20190104048A (ko) | 2017-01-06 | 2019-09-05 | 이오반스 바이오테라퓨틱스, 인크. | 종양 괴사 인자 수용체 슈퍼패밀리 (tnfrsf) 효능제를 사용한 종양 침윤 림프구 (til)의 확장 및 til과 tnfrsf 효능제의 치료 조합물 |
WO2018155525A1 (ja) * | 2017-02-23 | 2018-08-30 | ゼリア新薬工業株式会社 | 抗炎症剤 |
CN108623686A (zh) * | 2017-03-25 | 2018-10-09 | 信达生物制药(苏州)有限公司 | 抗ox40抗体及其用途 |
AR112072A1 (es) | 2017-06-05 | 2019-09-18 | Iovance Biotherapeutics Inc | Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario |
SG11202004457XA (en) | 2017-11-17 | 2020-06-29 | Iovance Biotherapeutics Inc | Til expansion from fine needle aspirates and small biopsies |
EP3737743A1 (en) | 2018-01-08 | 2020-11-18 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
US20210137930A1 (en) | 2018-02-13 | 2021-05-13 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists |
BR112020021660A2 (pt) | 2018-04-27 | 2021-02-02 | Iovance Biotherapeutics, Inc. | métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, composição de criopreservação |
BR112020026798A2 (pt) * | 2018-07-03 | 2021-03-30 | University Of Miami | Composições e métodos para o tratamento de doenças ou condições relacionadas com o inflamassoma |
TW202031273A (zh) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | 抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療 |
SG11202101787XA (en) | 2018-09-20 | 2021-04-29 | Iovance Biotherapeutics Inc | Expansion of tils from cryopreserved tumor samples |
AU2019347934A1 (en) * | 2018-09-26 | 2021-04-08 | Jiangsu Hengrui Medicine Co., Ltd. | An anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use |
US20220033775A1 (en) | 2018-11-05 | 2022-02-03 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathways inhibitors |
AU2019374761A1 (en) | 2018-11-05 | 2021-06-10 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
US20230039976A1 (en) | 2018-11-05 | 2023-02-09 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
BR112021008549A2 (pt) | 2018-11-05 | 2022-01-04 | Iovance Biotherapeutics Inc | Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor |
CN113348180B (zh) * | 2018-11-20 | 2023-05-26 | 上海开拓者生物医药有限公司 | Ox40抗体及其制备方法和应用 |
CN109651510B (zh) * | 2018-12-04 | 2023-03-24 | 上海长征医院 | 抗Eno1抗体及其用途 |
EP3898949A1 (en) | 2018-12-19 | 2021-10-27 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
AU2020215725A1 (en) * | 2019-02-01 | 2021-09-23 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
KR20220002336A (ko) | 2019-03-29 | 2022-01-06 | 미스트 쎄라퓨틱스, 엘엘씨 | T 세포 치료제를 제조하기 위한 생체외 방법 및 관련 조성물 및 방법 |
WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
CA3155727A1 (en) | 2019-10-25 | 2021-04-29 | Cecile Chartier-Courtaud | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
WO2021108727A1 (en) | 2019-11-27 | 2021-06-03 | Myst Therapeutics, Inc. | Method of producing tumor-reactive t cell composition using modulatory agents |
EP4073236A1 (en) | 2019-12-11 | 2022-10-19 | Iovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
EP4110799A1 (en) | 2020-02-27 | 2023-01-04 | Myst Therapeutics, LLC | Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof |
JP2023524108A (ja) | 2020-05-04 | 2023-06-08 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 改良された腫瘍反応性t細胞の選択 |
EP4146794A1 (en) | 2020-05-04 | 2023-03-15 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
JP2023546359A (ja) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 腫瘍浸潤リンパ球療法によるnsclc患者の治療 |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
CA3187272A1 (en) | 2020-10-08 | 2022-04-14 | Thorsten Ross | Trispecific binders |
CA3201818A1 (en) | 2020-12-11 | 2022-06-16 | Maria Fardis | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
US20240123067A1 (en) | 2020-12-17 | 2024-04-18 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocyte therapies |
AU2021401302A1 (en) | 2020-12-17 | 2023-07-06 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
BR112023021665A2 (pt) | 2021-04-19 | 2023-12-19 | Iovance Biotherapeutics Inc | Método para tratar um câncer, e, composição |
CA3226942A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
CA3216098A1 (en) | 2021-07-30 | 2023-02-02 | Uwe Reusch | Duplexbodies |
CA3235824A1 (en) | 2021-10-27 | 2023-05-04 | Frederick G. Vogt | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2024056862A1 (en) | 2022-09-15 | 2024-03-21 | Avidicure Ip B.V. | Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5821332A (en) * | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
US5759546A (en) * | 1994-02-04 | 1998-06-02 | Weinberg; Andrew D. | Treatment of CD4 T-cell mediated conditions |
US6057421A (en) * | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
DE60317677T2 (de) * | 2002-06-13 | 2008-10-30 | Crucell Holland B.V. | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung |
US20040136992A1 (en) * | 2002-08-28 | 2004-07-15 | Burton Paul B. J. | Compositions and method for treating cardiovascular disease |
DE602005018325D1 (de) * | 2004-02-19 | 2010-01-28 | Genentech Inc | Antikörper mit korrigierten cdr |
CA2605024C (en) * | 2005-04-15 | 2018-05-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
BRPI0621065A2 (pt) * | 2005-12-16 | 2011-11-29 | Genentech Inc | anticorpo anti-ox40l, anticorpos isolados, polinucleotìdeo, vetor, célula hospedeira, método para fabricar um anticorpo anti-ox40l, método para tratar ou previnir uma disfunção imune, composição e uso de um anticorpo anti-ox40l |
-
2008
- 2008-02-26 KR KR1020097020065A patent/KR20100014588A/ko not_active Application Discontinuation
- 2008-02-26 JP JP2009551698A patent/JP2010518873A/ja not_active Withdrawn
- 2008-02-26 WO PCT/US2008/002498 patent/WO2008106116A2/en active Application Filing
- 2008-02-26 MX MX2009009194A patent/MX2009009194A/es unknown
- 2008-02-26 AU AU2008219666A patent/AU2008219666A1/en not_active Abandoned
- 2008-02-26 CL CL200800578A patent/CL2008000578A1/es unknown
- 2008-02-26 CA CA002679399A patent/CA2679399A1/en not_active Abandoned
- 2008-02-26 EP EP08726081A patent/EP2125891A2/en not_active Withdrawn
- 2008-02-26 BR BRPI0807269-8A2A patent/BRPI0807269A2/pt not_active IP Right Cessation
- 2008-02-26 US US12/526,550 patent/US20100136030A1/en not_active Abandoned
- 2008-02-26 RU RU2009135824/10A patent/RU2009135824A/ru not_active Application Discontinuation
- 2008-02-26 CN CN200880013914A patent/CN101668776A/zh active Pending
- 2008-02-27 PE PE2008000393A patent/PE20090689A1/es not_active Application Discontinuation
- 2008-02-27 AR ARP080100818A patent/AR065506A1/es unknown
- 2008-02-27 TW TW097106870A patent/TW200846367A/zh unknown
-
2009
- 2009-08-25 IL IL200572A patent/IL200572A0/en unknown
- 2009-09-10 MA MA32212A patent/MA31246B1/fr unknown
- 2009-09-23 CO CO09103883A patent/CO6231009A2/es not_active Application Discontinuation
- 2009-09-24 CR CR11042A patent/CR11042A/es unknown
- 2009-09-25 EC EC2009009656A patent/ECSP099656A/es unknown
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9163085B2 (en) | 2010-08-23 | 2015-10-20 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of treating cancer |
US9527917B2 (en) | 2010-08-23 | 2016-12-27 | Board Of Regents, The University Of Texas System | Nucleic acid encoding anti-OX40 antibodies |
US9695246B2 (en) | 2010-08-23 | 2017-07-04 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
US10196450B2 (en) | 2010-08-23 | 2019-02-05 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
US10851173B2 (en) | 2010-08-23 | 2020-12-01 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
Also Published As
Publication number | Publication date |
---|---|
MX2009009194A (es) | 2009-10-08 |
PE20090689A1 (es) | 2009-06-20 |
CA2679399A1 (en) | 2008-09-04 |
MA31246B1 (fr) | 2010-03-01 |
WO2008106116A2 (en) | 2008-09-04 |
JP2010518873A (ja) | 2010-06-03 |
AR065506A1 (es) | 2009-06-10 |
AU2008219666A1 (en) | 2008-09-04 |
CR11042A (es) | 2009-11-03 |
CO6231009A2 (es) | 2010-12-20 |
IL200572A0 (en) | 2010-05-17 |
TW200846367A (en) | 2008-12-01 |
ECSP099656A (es) | 2009-10-30 |
EP2125891A2 (en) | 2009-12-02 |
US20100136030A1 (en) | 2010-06-03 |
WO2008106116A3 (en) | 2008-10-16 |
BRPI0807269A2 (pt) | 2014-04-29 |
KR20100014588A (ko) | 2010-02-10 |
RU2009135824A (ru) | 2011-04-10 |
CN101668776A (zh) | 2010-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008000578A1 (es) | Anticuerpo antagonista aislado anti-receptor ox40 humano; molecula de acido nucleico que lo codifica; vector y celula huesped; metodo de produccion; composicion que lo comprende; su uso para tratar trastornos mediados por ox40; y metodo para detectar | |
CL2007003807A1 (es) | Anticuerpos humanos anti-cd44 o fragmentos de los mismos; acidos nucleicos que los codifican; vector y celula huesped que los comprende; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar los sintomas de trastornos mediado | |
CL2007002987A1 (es) | Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para tratar enfermedades relacionadas con notch3. | |
CL2007003623A1 (es) | Proteina de enlace multivalente monocatenaria con funcion efectora; acido nucleico que la codifica; vector y celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y metodo para tratar trastornos proliferativos. | |
CL2007002835A1 (es) | Anticuerpo monoclonal especifico para el receptor cxcr4; acido nucleico que lo codifica; vector y celula que lo comprenden; metodo de produccion; inmunoconjugado y composicion que lo comprende; y su uso para tratar cancer, trastornos inflamatorios y | |
CL2008000839A1 (es) | Anticuerpo anti-ige/m1'; acido nucleico que lo codifica; vector y celula huesped; proceso de produccion; composicion que comprende al anticuerpo; y su uso para tratar trastornos mediados por ige. | |
CL2008001129A1 (es) | Variente de asparraginasa; secuencia de acido nucleico que la codifica; construccion de acidos nucleicos; vector y celula huesped; metodo para producir asparraginasa; composicion que comprende la variante; uso de la variante de asparraginasa; proceso | |
CL2017000772A1 (es) | Anticuerpo aislado que se une a mesotelina; ácido nucleico que lo codifica; célula huésped; método de producción; inmunoconjugado; formulación farmacéutica que lo comprende; su uso para tratar cáncer; y método de detección de mesotelina humana. (divisional solicitud 1776-2013) | |
CL2008000935A1 (es) | Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige. | |
CL2008000478A1 (es) | Elemento de union aislado especifico para inmunoglobulina e (ige); molecula de acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y su uso para tratar trastornos asociados con ige. | |
CL2007003445A1 (es) | Compuesto aislado de union a interleuquina-6 (il-6) humana; acido nucleico que lo codifica; metodo de produccion; composicion que los comprende; y su uso para tratar desordenes asociados con il-6. | |
CL2013003336A1 (es) | Anticuerpo anti-cgrp humano; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica y diagnostica que lo comprende; y su uso terapéutico | |
BR112015020277A2 (pt) | moléculas de ligação para bcma e cd3 | |
CL2008001673A1 (es) | Dominio variable simple de la inmunoglobulina del receptor tipo 1 de la anti-interleucina 1 (il-1r1); acido nucleico que lo codifica; vector y celula huesped; metodo de produccion; antagonista de il-1r1 que lo comprende; composicion que comprende al antagonista; y uso del antagonista para tratar una condicion inflamatoria. | |
BRPI0915928A2 (pt) | composições e métodos de uso para anticorpos terapêuticos | |
CL2013000930A1 (es) | Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17. | |
CL2015002526A1 (es) | Anticuerpos anti-ox40 y métodos de uso de los mismos.(divisional de 545-13). | |
CL2007002989A1 (es) | Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para el diagnostico de enfermedades relacionadas con notch3. | |
CL2013002062A1 (es) | Anticuerpo monoclonal que se une al gen 3 de la activacion linfocitaria (lag-3) humana; composicion que comprende dicho anticuerpo; molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que lo comprende: metodo de preparacion; y su uso para estimular la respuesta inmune. | |
CL2013003728A1 (es) | Anticuerpo antagonista o fragmento del mismo que se une a ox40 de humano; epitope del dominio extracelular de ox40 de humano que es unido por en anticuerpo antes mencionado; acido nucleico que codifica el anticuerpo; vector y célula hospedera que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion que comprende el anticuerpo; inmunoconjugado; uso para tratar trastornos mediados por ox40. | |
CL2007002412A1 (es) | Anticuerpo especifico para el dominio extracelular del receptor de prolactina (prlr); molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que la comprenden; metodo de produccion; composicion farmaceutica que comprende al | |
BR112014010940A2 (pt) | moléculas de ligação para bcma e cd3 | |
BR112014006390A2 (pt) | anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano | |
CL2014000631A1 (es) | Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer. | |
BRPI0817812A2 (pt) | Uso de anticorpos trkb para o tratamento de distúrbios respiratórios |